Dirk Sibbing: Potent P2Y12 Inhibition in Patients With Atrial Fibrillation and Acute Coronary Syndrome
Dirk Sibbing, Cardiologist and Angiologist at Lauterbacher Mill Private Clinic and LMU Munich, shared a post on LinkedIn about a recent article he and his colleagues co-authored, published in Nature Medicine, adding:
“EPIDAURUS Trial – presented at ESC 2026 and published simultaneously in nature medicine
DOAC plus potent P2Y12 inhibition vs. DOAC plus clopidogrel and in-hospital aspirin in ACS patients (n=602) with atrial fibrillation undergoing PCI
Treatment with a potent P2Y12 inhibitor was associated with higher bleeding rates without a clear reduction in the risk of ischemic complications
Key take: More potent platelet inhibition does not necessarily result in less ischemic events
Clinical scenarios differ in terms of assets and drawbacks of potent platelet inhibition with prasugrel or ticagrelor
Congratulations to Prof. Dr. med. Konstantinos Rizas and Prof. Dr. med. Steffen Massberg at Cardio LMU for the trial lead and for bringing together so many cardiologists for this multi-centre RCT
Please see our results published in Nature Medicine”
Title: Dual antithrombotic therapy using potent antiplatelet inhibitors in atrial fibrillation and acute coronary syndrome: a randomized controlled trial
Authors: Konstantinos D. Rizas, Konstantinos Mourouzis, Dominik Rath, Christoph B. Olivier, Laura Elisa Villegas Sierra, Theofanis Korovesis, Amin Polzin, Amani Al Tawil, Reza Wakili, Lukas von Stuelpnagel, Katharina Mayer, Marion Janisch, Tanja Ulrich, Sarah Lang, Sebastian K. G. Maier, Florian Brattinger, Lorenz Bott-Flügel, Harilaos Bogossian, Konstantinos Iliodromitis, Luisa Freyer, Julius Steffen, Konstantin Stark, Elodie Eiffener, Lauren E. Sams, Tobias Petzold, Axel Linke, Felix M. Heidrich, Samuel Sossala, Saif Zako, Nikolaos Dagkonakis, Andreas Schäfer, Frank Edelmann, David M. Leistner, Mariya Maslarska, Fabian Knebel, Georg Nickenig, Blerim Luani, Tienush Rassaf, Hüseyin Ince, Ibrahim Akin, Micha T. Maeder, Meinrad Gawaz, Hans-Josef Feistritzer, Norbert Frey, Stefan Kääb, Riza Sahin, Matthias Pauschinger, Thomas Stiermaier, Ingo Eitel, Marc Kollum, Jan Sebastian Wolter, Michael Schreinlechner, Axel Bauer, Christoph Stellbrink, Ulf Landmesser, Paulus Kirchhof, Dirk Sibbing, Holger Thiele, Adnan Kastrati, Ulrich Mansmann, Steffen Massberg
Stay updated on all scientific advances with Hemostasis Today.
-
Oct 9, 2026, 11:44Ayyappan V Nair: PRP and Rehabilitation – Can It Help Athletes with Partial Rotator Cuff Tears?
-
Oct 9, 2026, 11:29Jigesha Dholakia: Supporting the Hemophilia Community Through the Unite Walk
-
Oct 9, 2026, 11:06Nobles Green: How siRNA Therapy Helps the Body Form Stronger Clots
-
Oct 9, 2026, 10:53Switching From Emicizumab to Denecimig in Hemophilia A – Rare Disease Advisor
-
Oct 9, 2026, 10:40What New U.S. Data Reveal About GT – Glanzmann’s Research Foundation
-
Oct 9, 2026, 10:32Anjali Pandey: The Morphologic Clues to MDS With del(5q)
-
Oct 9, 2026, 10:13Reza Shojaei: 5 Leadership Responsibilities for a Sustainable Plasma Ecosystem
-
Oct 9, 2026, 08:38Johannes Gratz: Perioperative Care in Factor VII Deficiency – Treating the Patient, Not the Number
-
Oct 9, 2026, 08:28Ghanim Fajish: Vascular Cells May Retain a Prothrombotic Memory of Oxidative Stress